Moderna's experimental melanoma vaccine has shown promising results in preventing the recurrence of the deadly skin cancer, according to new clinical trial data. The personalized mRNA vaccine, designed specifically for individual patients, demonstrated high effectiveness when used in combination with Keytruda, an established immunotherapy drug.

The vaccine works by training the immune system to recognize and attack cancer cells that might remain after initial treatment. Clinical trial results indicate the treatment significantly reduced the risk of melanoma returning over a five-year period compared to standard care alone.

The development represents part of a broader trend in personalized cancer treatment, where therapies are tailored to individual patients' specific tumor characteristics. The vaccine is created using the same mRNA technology platform that Moderna used for its COVID-19 vaccines, repurposed for cancer treatment.

Meanwhile, Moderna has also received $60 million in funding, along with other research groups, to develop vaccines for Ebola virus. The company continues to expand its mRNA vaccine platform beyond COVID-19 applications into other infectious diseases and cancer treatments.

The melanoma vaccine remains experimental and has not yet received regulatory approval. Further clinical trials and regulatory review will be required before the treatment becomes available to patients outside of research settings.